HUNTINGTON INGALLS INDUSTRIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HUNTINGTON INGALLS INDUSTRIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.48B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $11.54B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $11.45B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $10.68B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $9.52B | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | $2.76B | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $2.31B | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $2.03B | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $2.26B | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $2.41B | Feb 11, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.00B | Feb 15, 2018 |
| FY2017 | Sep 30, 2017 | $1.86B | Feb 15, 2018 |
| FY2017 | Jun 30, 2017 | $1.86B | Feb 15, 2018 |
| FY2017 | Mar 31, 2017 | $1.72B | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $1.92B | Feb 15, 2018 |
| FY2017 | Sep 30, 2016 | $1.68B | Feb 15, 2018 |
| FY2017 | Jun 30, 2016 | $1.70B | Feb 15, 2018 |
| FY2017 | Mar 31, 2016 | $1.76B | Feb 15, 2018 |
| FY2016 | Dec 31, 2015 | $1.91B | Feb 16, 2017 |
| FY2016 | Sep 30, 2015 | $1.80B | Feb 16, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $605.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $550.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $681.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $579.00M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $544.00M | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | $249.00M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $222.00M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $53.00M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $172.00M | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $149.00M | Feb 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $657.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $535.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $781.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $565.00M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $513.00M | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | $305.00M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $222.00M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $57.00M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $215.00M | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $186.00M | Feb 11, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $27.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $35.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $40.00M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $34.00M | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $31.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $23.00M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $25.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $17.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $19.00M | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $393.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $970.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $766.00M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $760.00M | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $1.09B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $896.00M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $914.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $814.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $822.00M | Feb 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $402.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $367.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $292.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $284.00M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $331.00M | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $353.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $530.00M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $463.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $382.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $285.00M | Feb 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.75B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $12.14B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $11.22B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $10.86B | Feb 1, 2024 |
| FY2023 | Dec 31, 2021 | $10.63B | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $8.16B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $7.03B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $6.38B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $6.37B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $6.35B | Feb 14, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.68B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $7.48B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $7.12B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $7.37B | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.82B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $6.26B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $5.44B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $4.87B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $4.62B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $4.70B | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.07B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.67B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $4.09B | Feb 5, 2026 |
| FY2025 | Dec 31, 2022 | $3.49B | Feb 5, 2026 |
| FY2024 | Dec 31, 2021 | $2.81B | Feb 6, 2025 |
| FY2023 | Dec 31, 2020 | $1.90B | Feb 1, 2024 |
| FY2022 | Dec 31, 2019 | $1.59B | Feb 9, 2023 |
| FY2021 | Dec 31, 2018 | $1.52B | Feb 10, 2022 |
| FY2020 | Dec 31, 2017 | $1.76B | Feb 11, 2021 |
| FY2019 | Dec 31, 2016 | $1.65B | Feb 13, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.65B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.62B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $2.62B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $2.62B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $2.63B | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $1.62B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $1.37B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $1.26B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $1.22B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.23B | Feb 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.49B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $5.10B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $4.76B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $4.28B | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.89B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $3.53B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $3.01B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $2.61B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.69B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.32B | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $627.00M | Feb 10, 2022 |
| FY2021 | Dec 31, 2020 | $512.00M | Feb 10, 2022 |
| FY2021 | Dec 31, 2019 | $75.00M | Feb 10, 2022 |
| FY2021 | Dec 31, 2018 | $240.00M | Feb 10, 2022 |
| FY2020 | Dec 31, 2017 | $701.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2016 | $720.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2015 | $894.00M | Feb 14, 2019 |
| FY2017 | Dec 31, 2014 | $990.00M | Feb 15, 2018 |
| FY2016 | Dec 31, 2013 | $1.04B | Feb 16, 2017 |
| FY2015 | Dec 31, 2012 | $1.06B | Feb 18, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.91B | Feb 9, 2023 |
| FY2022 | Dec 31, 2021 | $3.30B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.69B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.29B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.28B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.28B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.28B | Feb 15, 2018 |
| FY2016 | Dec 31, 2015 | $1.27B | Feb 16, 2017 |
| FY2015 | Dec 31, 2014 | $1.67B | Feb 18, 2016 |
| FY2014 | Dec 31, 2013 | $1.78B | Feb 19, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 13 | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 17 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 14 | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | 13 | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | 6 | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | 5 | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | 4 | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | 3 | Feb 11, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 13 | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 17 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 14 | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | 13 | Feb 1, 2024 |
| FY2020 | Dec 31, 2020 | 6 | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | 5 | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | 4 | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | 3 | Feb 11, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.24M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 39.13M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | 39.62M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | 39.86M | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | 40.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | 40.50M | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | 40.80M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | 41.90M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | 45.10M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | 46.20M | Feb 15, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $213.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $206.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $200.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $192.00M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $186.00M | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $172.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $149.00M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $132.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $115.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $98.00M | Feb 14, 2019 |